Marburg

• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• UNITAS Ended
  2022-502483-21-00 4 2023-07-28 Insomnia disorder
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 Moderate-to-Severe Uncontrolled Asthma
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch … Ended
  2024-516988-87-00 4 2022-11-09 Chronic Inducible Urticaria
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 5 2022-05-17 refractory, advanced gastro-oesophageal cancer
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended
  2023-508571-37-00 4 2022-04-29 Geographic atrophy (GA) secondary to Age-related Macular Degeneration
• SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra … Ended
  2024-515731-29-00 4 2022-03-30 advanced stage hepatocellular carcinoma
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503572-24-00 5 2022-03-02 Chronic Obstructive Pulmonary Disease (COPD)
• GRAPPA Ended
  2023-510441-24-00 5 2022-01-28 Graft Vs Host Disease Peripheral Blood Stem Cell Transplantation AML M
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-507093-40-00 4 2022-01-27 Chronic Obstructive Pulmonary Disease (COPD)
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended
  2024-510745-34-00 10 2020-11-11 Bullous Pemphigoid
• Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended
  2023-507221-42-00 5 2020-06-03 Acute Myeloid Leukemia in First Remission
• Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended
  2024-514018-12-00 9 2020-04-06 female and male adult patients with acute myeloid leukemia (AML) at fi
• Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Ended
  2024-515827-12-00 1 2020-01-28 Acute Myeloid Leukemia (AML)

Showing 145–168 of 179 trials